Experts convene at World Conference on Tobacco OR Health meeting to discuss reducing global tobacco use and accessibility to treatment options
MUMBAI, India, March 9 /PRNewswire/ -- GlaxoSmithKline (GSK) Consumer Healthcare today announced plans to increase the availability of their therapeutic nicotine products to reach more than 800 million people world-wide over the next four years. The announcement was made at the World Conference on Tobacco OR Health (WCTOH) meeting held this year in India, a country on pace to see nearly one million smoking-related deaths per year by 2010(1). Thought leaders from around the globe gather at this triannual conference to discuss global initiatives under way to reduce tobacco use and its extraordinary health toll.
"GSK plans to introduce our quit smoking aids to 85 percent of the world's smokers by 2013. We are committed to finding approaches, in concert with local experts, to maximize the access and impact of our life-saving products," said Raj Mishra, MD, PhD, vice president research and development, GlaxoSmithKline Consumer Healthcare. "Our hope is that by launching our therapeutic nicotine products globally we will be doing our part to help reduce the global burden from tobacco-related disease by helping more smokers quit."
A World Health Organization (WHO) global tobacco report found that tobacco use was increasing most rapidly in low-income countries due to steady population growth coupled with tobacco industry efforts. In fact, the report states that without a commitment to helping smokers quit, a projected one billion smokers will die prematurely from tobacco this century(2). As part of their outlined policy, the WHO encourages leaders in the fight against tobacco to offer help to quit tobacco use through three types of treatment - telephone counselling, cessation advice in primary healthcare services and pharmacotherapy including the use of therapeutic nic
'/>"/>
| SOURCE GlaxoSmithKline Consumer Healthcare Copyright©2009 PR Newswire. All rights reserved |